Reduction in surgical site infections by localized administration with D-PLEX100 in patients with multiple risk factors undergoing colorectal surgery

Anthony J. Senagore*, Yafit Stark, Olga Belotserkovsky, Malka Reichert, Nir Wasserberg, Hagit Tulchinsky, Lior Segev, Oded Zmora, Goldi A. Kozloski, Noam Emanuel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: D-PLEX100 is a novel drug-eluting lipid polymer matrix that supplies a high, local concentration of doxycycline for approximately 30 days. The objective of this post-hoc analysis was to assess the efficacy of D-PLEX100 in preventing superficial and deep SSIs in patients with ≥2 risk factors. Patients and methods: A post-hoc analysis of a previously reported prospective randomized trial assessing D-PLEX100 plus Standard of Care (SOC) versus SOC alone in colorectal surgery was performed to assess SSI rate in patients with ≥2 risk factors. Results: The overall incidence of SSI was significantly lower for the D-PLEX100 arm (9.9%) versus SOC (21%), p = 0.033. Patients with ≥2 risk factors, SSI incidence was 37.5% for SOC and 15.8% in D-PLEX100 treated patients. Conclusions: D-PLEX100 reduces the incidence of SSIs beyond benefits associated with SOC treatment alone and including patients with ≥2 risk factors. D-PLEX100 may be a promising addition to established SSI prophylaxis bundles.

Original languageEnglish
Pages (from-to)485-488
Number of pages4
JournalAmerican Journal of Surgery
Volume225
Issue number3
DOIs
StatePublished - Mar 2023
Externally publishedYes

Keywords

  • Doxycycline
  • Localized antibiotic therapy
  • Risk factors
  • Surgical site infection

Fingerprint

Dive into the research topics of 'Reduction in surgical site infections by localized administration with D-PLEX100 in patients with multiple risk factors undergoing colorectal surgery'. Together they form a unique fingerprint.

Cite this